Trials / Active Not Recruiting
Active Not RecruitingNCT04116047
CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
Phase III Randomised Controlled Trial Comparing Alternative Regimens for Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 785 (estimated)
- Sponsor
- University of Birmingham · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
CompARE is a multicentre, phase III open-label randomised controlled trial using an adaptive, Multi-Arm, Multi-Stage (MAMS) design.
Detailed description
The CompARE Trial examines alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer in an adult patient population. The aim is to assess whether escalated radiotherapy, adding surgery or immunotherapy will improve overall survival and quality of life in these patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cisplatin | |
| DRUG | Durvalumab | |
| PROCEDURE | Radiotherapy |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2026-12-01
- Completion
- 2030-12-01
- First posted
- 2019-10-04
- Last updated
- 2024-07-29
Locations
38 sites across 2 countries: Ireland, United Kingdom
Source: ClinicalTrials.gov record NCT04116047. Inclusion in this directory is not an endorsement.